A few short greedy crooks just converged on the issue this morning. They made money on a their retail client accounts by spreading a negative article and piling on shorted shares.
Our little crooked short trader strikes again. Do they ever catch this guy at his games. That had to be the bogus move down of the year.
Edit to previous post: The problem for him is that most investors who bought post approval, at higher prices, may not sell this stock in Dec because the Otrexup launch is in Jan.They would be subject to wash sales if they try to buy back in Jan. This is also his target group or the retail investors he is trying to get over on. Our short is also giving up other opportunities while he is wasting his time on a stock with very little downside and plenty of upside. He will likely move on or go net long before the Jan Effect and the launch.
This is a historic fact. There is not a lot of downside side to this stock from now to Jan 2014. Our short should try to cover during this month because it traditionally a month when investors create tax losses to off-set their capital gains for the year. This is the weakness he is looking for. Otrexup will launch is JAN 2014, small stocks normally rise during that month. I am sure our short sell is aware of this and will try to cover before the JAN Effect.
The for him is that most investors may not sell this stock in Dec because the launch is in Jan.They would be subject to wash sales if they try to buy back in. Our short is also giving other opportunities while he is wasting his time on a stock with very little downside and plenty of upside. He will likely move on this month to something else.
We should see our short cover some between now and JAN 2014. Small stocks normally do well during this time of year. I see he is trying to push it down on weakness. He is running out of time and shares to short. The Otrexup launch will also add to the JAN effect of this stock. He is getting desperate.
" I think one of the biggest mistakes people have made with this stock (and I am one of them) is we keep thinking Paul and the gang have the ammo necessary to ignite a fire under this at any time and they choose not to for whatever reason."
Management is concerned more with developing and marketing the product of this company to add shareholder value. So far, it has done a very good job. All they can do is direct investors attention to the positive of the company. They are also very conservation in their projections.
The patient target of about 25000 is a pretty reasonable assumption for a saleforce of 25. At $7000 per patient a year, the company should not have a problem achieving $150 million in revenue, esp when it includes the other products. Also, product growth cycles rates are normally slower in the introduction stage. They gain traction as patients adapt to products. A strong marketing team will be the key here. It looks like the company has one in place for the Otrexup launch.
Our short seller is trying to get a lot of money from small retail investors accounts. This has nothing to do with Paul and co. Retail investors bought a lot of shares of this company post approval. This is his target. He considers them weaker than institutional investors and easy targets.
This stock still has a positive trend line base date 01/01/2013. The only exception is when a short seller started a negative rumor on or about 09/16/2013. The rumor stated that the FDA leaked an Otrexup CRL. It was totally untrue but investors put weight on it anyway. This in turn caused negative sentiment towards the stock which resulted in a decrease in price. Some authors at SA dispelled this rumor later by by writing article to explain to investors it was just that....a false negative rumor. Price recovered but I imagine our short seller started calling around to get a fund manager to sell into any post approval rallies. This was likely also associated with negative overtones about the stock, company and retail investors ( the targets).
The stock price should retrace to the post approval high after the it unwinds these negatives and investors become more confident in the company and the stock. Sometime better to view stock price fluctuations as data on a scatter plot. Take the base and then draw a line through to the end data. Six months of date points are better than one month. Our short seller has been working on this stock and investors accounts for about a month now. He will likely exit his position when weak investors sell their shares to him or when strong investors push the price up on him. He is not looking at a lot of upside by holding his short position past the end of this year, so he will likely play his games until the first quarter of 2014. The upside to this stock and company for outweighs the downside. We may see $6 if the QST trials are positive combined with the Otrexup launch and the approval of one or two of the TEVA products.
I am relaxed knowing there is only a short here causing all the problems. The point is that it is not uncommon for shorts to pay cross-border groups (boiler rooms) to post negative comments about companies. Thai is notoriously used by shorts for these boiler room short and distort scams design to rip off unsuspecting investors. I am sure our short seller is watching these boards to find anything negative to post about this company. He is on their accounts information and shares of about 17 million trying to get paid. I am sure he will try to cover his tracks here with cheap labor.
They would, if our short seller puts the shares back into their accounts at higher prices instead of trying to scam them. He thinks their shares are his but he is confused here. This stock is also due for a major increase in price. Short is just that, short term, he will have to cover at higher prices unless he has more tricks up his sleeves. His well is running dry.
[Police have warned the so-called "boiler room" scam networks have moved on from Nigeria and are active in Asia and on the Gold Coast.
The Australian Crime Commission said one scam in Bangkok was linked to the theft of more than $50 million from Australians.
The ACC said that in the Bangkok raid in April, Thai police found nine expats with phones, scripts and lists of Australians.
The scams use carefully crafted scripts to dupe Australians into investing.
ACC acting executive director Warren Gray said: "Any of the South-East Asian countries and China seem to be favoured for it.
"We're finding expats man the boiler rooms so that the language difficulty isn't too bad and they are believable stories.'']
Shorts also use these boiler room tactics to confuse investors. The target is small investors. The purpose is to steal from their accounts by borrowing their shares and posting negative posts throughout the net to drive down price. If the share values drops, they buy and replace the shares at lower prices. The trademark post is a non-issue.
That analogy is not the same and the issue is not material to ATRS or its shareholders. If there was an issue, the PFE lawyers would have called ATRS immediately. The company would have put out an 8K to inform its shareholders. Some people need to stop trying to be trademark lawyers. Someone is just wasting our time on a lot of nothing. Also, people write things to inform, persuade, give advice, etc.... The posting of this trademark issue does not has any substance to it. Also, it is not meant to inform or educate investors on complex trademark issues. If anything it only confuses a few investors.
The key is to solve the mysteries before the end of the plays. Let us see if you can solve the question of our mystery short seller and his plot. I love mysteries.
Price does communicate to us information about the markets but these theories often exclude short sellers and their efforts to manipulate market price. Some theorists only call them market manipulators. Question: Do you think AF was trying to be a market manipulator when he posted a negative article on the date of the Otrexup approval. Do you think the investor who posted the false rumor of a FDA Otrexup CRL leak tried to manipulate this stock price. Do you think our short seller is trying to be a market manipulator of this stock. Back to set theory: Are these events related to each other or can we exclude one or all of them from our short seller mystery.
I will be eating popcorn and waiting for the events to unfold in our short seller play. Your good at pick stock, so what will he do next.
This is really a non-issue for this stock and company. PFE is not a plaintiff nor is ATRS a defendant in any trademark case that involves OTREXUP or OTREXYO. PFE also does not have marketing dollars tied to this brand name or product similar to it with this brand name. Some people who don't know anything about patent and trademark laws are waiting their time on this issue. There is nothing to this argument.
Better to wait until we find out exactly what is going on with this stock. Someone is playing games with it right to cover their short positions. They are also trying ripoff their clients and small investors. I watch several stocks and this is the only one doing this.
I would not post buy orders on this board either. This is how they get your account information.
That is the best advise yet. This stock has several parties who are trying to push it down for some reason or a other. One reason is they are trying to steal money from investor accounts. Another reason they are trying to pay certain people back for complaining about it. The problem, the SEC is not doing anything to them because our parties played both sides of the fence. They pumped it, dumped it and then shorted it to drive down the stock price. Regulators will take action against pump and dump but they do very little to characters of short and distort scams. The same investor who helped pushed this stock up are now helping to push it down by pulling the liquidity, spreading negatives or not saying anything positive at all.
They are trying to steal money from your accounts period.
"Seizing The Blockbuster Opportunity Buried In Conservative Modeling At Antares Pharma." SA Ali Yasar
Maybe you should start reading your own comments. The questions and points I made on this board were raised by other people. WHAT KIND OF GAME ARE YOU PLAYING HERE WITH INVESTORS.
Don't bother Loko, he is just the fall guy for the rest of his group. He may not even know what he is doing by omitting certain facts from his posts and not correcting them when he has reason to believe that they are wrong. Years ago I also suspected a fund manager or someone with level III access was communication with them. I am almost sure this is the case now. This could not pick his way out of a paper bag a few years ago and now he is claiming fame to a perfect timing strategy. Something does not pan out here.
He also did not correct his State Street liquidation claim when he had reason to believe that the information was incorrect. He is a weak player anyway, meaning that if anyone knocks on his door asking questions, he will likely turn on the rest of his buddies. He is likely compiling all their emails just in case since he is the only one sticking his neck out here.
This stock has maybe a 10 cent downside to it and a upside north of $6. Someone is taking a lot of risk for a few cents gain.
Sounds like you invited our friend to a party when you already knew the answer. LOL. I have plenty of popcorn, lets see what else they will come up with to mislead investors. Whogo tried to start trouble with that post about competition. He knew the truth about the formation all the time. ATRS has exclusive rights to its formations in the U.S. Any company trying to put out formations anywhere close to them will be the subject of ongoing patent litigations.
Well, at least you figured it out. It is at a completely different dose and the FDA may not even approve a higher dosage. In the meantime, ATRS has exclusive market rights in the U.S for its formations at $7000 a year. Also, the autonomous demand for these products in the U.S is likely well over 200 thousand patients. With the copay patient cost would also not be that much. So we find that there is a growing demand for these products. ATRS is only looking to gain about 25000 patients in this market. This is conservative number considering the actual patient population is 1.5 million and the demand is a lot higher.